Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BW Therapeutics was a private U.S. biotechnology company based in Tampa, Florida, focused on oncology drug development. The company was founded in 2019 and centered its pipeline on TYN-21, described as a proprietary 505(b)(2) formulation of paclitaxel intended to provide equivalency to Abraxane. Publicly available information suggests BW Therapeutics pursued a relatively narrow, single-asset strategy and was seeking Series A financing and strategic partnering in early 2020. Company databases now list the business as closed, with no evidence of an approved product or active late-stage clinical pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BW Therapeutics.